REVIEW article

Front. Pharmacol.

Sec. Drugs Outcomes Research and Policies

Volume 16 - 2025 | doi: 10.3389/fphar.2025.1609791

This article is part of the Research TopicExploring the Applications of Artificial Intelligence in Disease Screening, Diagnosis, Treatment, and NursingView all 4 articles

Oxaliplatin-Induced Neuropathic Pain in Cancer: Animal Models and Related Research Progress

Provisionally accepted
Yuxin JiangYuxin Jiang1Jie ShiJie Shi2Mingzhu LiMingzhu Li3*Shengbo JinShengbo Jin1*Wenping WangWenping Wang3Haozhe PiaoHaozhe Piao3Huini YaoHuini Yao4Ju YuJu Yu1Zhenzhu ZhaiZhenzhu Zhai1Qian LiuQian Liu1Ningxin LiNingxin Li4Jiaqing FuJiaqing Fu1Yue ShenYue Shen1
  • 1Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning, China
  • 2Dalian Medical University, Dalian, Liaoning, China
  • 3Liaoning Cancer Hospital, China Medical University, Shenyang, China
  • 4China Medical University, Shenyang, Liaoning Province, China

The final, formatted version of the article will be published soon.

Select one of your emails

You have multiple emails registered with Frontiers:

Notify me on publication

Please enter your email address:

If you already have an account, please login

You don't have a Frontiers account ? You can register here

Oxaliplatin, a third-generation platinum-based chemotherapeutic agent, has shown substantial efficacy in cancer treatment. However, its associated side effects, particularly chemotherapy-induced peripheral neuropathic pain (CIPNP), continue to challenge cancer survivors globally. Clinically, it frequently presents as numbness, coldness, and discomfort in the limbs and extremities. Duloxetine is advised for analgesic purposes. Despite its clinical relevance, both the application methods and the underlying mechanisms of oxaliplatin-induced CINP warrant further investigation. Consequently, more precise animal models are needed to explore the mechanisms and progression of this condition. This review consolidates recent advancements in rat and mouse models of oxaliplatin-induced CINP, with the aim of enhancing modeling success rates and developing models that more accurately mirror disease progression. Such models are essential for advancing clinical research and drug development.

Keywords: oxaliplatin, neuropathic pain, CINP animal model, chemotherapy, applications

Received: 11 Apr 2025; Accepted: 13 May 2025.

Copyright: © 2025 Jiang, Shi, Li, Jin, Wang, Piao, Yao, Yu, Zhai, Liu, Li, Fu and Shen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Mingzhu Li, Liaoning Cancer Hospital, China Medical University, Shenyang, China
Shengbo Jin, Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Supplementary Material